Could a Virus-Like particle vaccine outsmart polio?

NCT ID NCT06577298

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial is testing an experimental vaccine made from virus-like particles (VLPs) that mimic polio viruses without causing disease. It aims to see if this vaccine is safe and triggers a strong immune response in healthy infants starting at 6 weeks old and toddlers aged 12-18 months. Participants receive either one of three doses of the VLP vaccine or a standard inactivated polio vaccine, with multiple doses given over several months. The study compares side effects and antibody levels to determine the best dose for future use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A virus-like particle (VLP) based vaccine against poliomyelitis, given in different doses with an adjuvant, compared to an inactivated polio vaccine (IPV).
What this could lead to
If successful, this could provide a safer, more effective polio vaccine option that does not rely on live or inactivated whole viruses, potentially improving global polio eradication efforts.
What could go wrong
This is an early-phase trial, so the vaccine may not produce a strong enough immune response or may cause unexpected side effects. Results in infants and toddlers may not predict effectiveness in broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLIOMYELITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dr. Cipto Mangunkusumo Hospital

    Jakarta, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.